Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Shenzhen Qianhai Beizeng Asset Management

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 4
Average round size
info
The average size of a deal this fund participated in
$12M
Portfolio companies 4
Lead investments 0
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical Device
  • Medical

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Altara Ventures Central, Central Region, Singapore
Arkea Capital Investissement France, Ile-de-France, Paris
Bravo Equity Partners -
Gemcorp England, London, United Kingdom
Goldrock Media LLC New York, New York, United States
Good Capital Group China, Jiangsu, Nanjing
Guangzhou Finance Holdings China, Guangdong, Guangzhou
HA-LO Industries Illinois, Sterling, United States
Haatch Lincolnshire, Stamford, United Kingdom
ICP England, London, United Kingdom
IT Capital Canada, Markham, Ontario
NGM Ventures -
Octalfa Écully, France, Rhone-Alpes
Scale AI California, San Francisco, United States
Tanium Kirkland, United States, Washington
UBS O'Connor Chicago, Illinois, United States
Wuhu Construction Investment Anhui, China, Wuhu
Zeeuws Investerings Fonds Netherlands, Vlissingen, Zeeland

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Sanyou Bio

Biometrics
Biotechnology
Pharmaceutical
02 Aug 2022 Shanghai, Shanghai, China

Jisi Yingda

Biopharma
Biotechnology
Pharmaceutical
15 Nov 2021 Shanghai, Shanghai, China

Hisky Medical

Health Care
Health Diagnostics
Medical
Medical Device
$15M17 Aug 2021 Haidian District, Beijing, China

Biotechnology
Health Care
$36M05 Jul 2019 Hexi, Tianjin, China

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Shenzhen Qianhai Beizeng Asset Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: